Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study

Respirology : Official Journal of the Asian Pacific Society of Respirology
Tsuyoshi HamadaKazuhiko Koike

Abstract

Interstitial lung disease (ILD) is a widely recognized adverse consequence of gemcitabine administration, but data on gemcitabine-associated ILD are limited. This study aimed to elucidate the incidence and risk factors for this adverse event. Patients who underwent gemcitabine-based chemotherapy between July 2010 and March 2013 were retrospectively identified using a Japanese nationwide administrative database. ILD was defined according to the International Classification of Diseases and Related Health Problems 10th Revision, codes: J70.2-70.4, J84.1 and J84.9. The cumulative incidence and risk factors for ILD were evaluated using a competing risk analysis. In total, 25 924 patients who underwent gemcitabine-based chemotherapy were identified from 331 hospitals (primary cancer; pancreatic, urothelial, biliary tract, lung, ovarian and breast, in 9070, 5578, 4803, 4388, 1339 and746 patients, respectively). ILD was observed in 428 patients (1.7%), and the cumulative incidence was estimated at 1.1% (95% CI: 1.0-1.2%), 1.5% (95% CI: 1.4-1.7%) and 1.9% (95% CI: 1.7-2.1%) at 3, 6 and 12 months, respectively. In the multivariable regression model, age >80 years and lung cancer were the strongest predictors for ILD (subdistribution haza...Continue Reading

References

Jun 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J B LesesneP S Schein
Nov 1, 1982·Southern Medical Journal·J MilutinovicM Fisher
Feb 2, 2002·American Journal of Clinical Oncology·Niraj GuptaBhoomi Mehrotra
Aug 31, 2002·Investigational New Drugs·Debasish F RoychowdhuryMichael Arning
Jan 30, 2004·Fundamental & Clinical Pharmacology·Fabrice BarlésiJean-Pierre Kleisbauer
Aug 7, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Claudia E RübeChristian Rübe
Sep 2, 2004·British Journal of Cancer·P CamusM Ebina
Sep 2, 2004·British Journal of Cancer·T HigenbottamY Fujita
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christer SederholmSulochana R Gawande
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Aug 6, 2011·Journal of Cancer Research and Clinical Oncology·Shigeki UmemuraHaruhito Kamei
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler

❮ Previous
Next ❯

Citations

May 26, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Adelle S JeeAmanda Piper
Oct 27, 2018·BJR Case Reports·Francesca ComitoMariacristina Di Marco
Nov 7, 2019·Current Pharmaceutical Design·Eva Rebelo GomesFrederico Regateiro
Aug 31, 2016·Expert Review of Anti-infective Therapy·D LeoniJ Rello
Oct 18, 2018·Journal of Clinical Medicine·Sarah SkeochNazia Chaudhuri
Nov 12, 2020·International Journal of Clinical Oncology·Tsuyoshi TakedaNaoki Sasahira

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.